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Clinical Perspectives of Genetic Analyses on Dyslipidemia and 
Coronary Artery Disease
Hayato Tada, Masa-aki Kawashiri and Masakazu Yamagishi
Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, Kanazawa, Japan
We have learned that low-density lipoprotein (LDL) cholesterol is the cause of atherosclerosis from 
various aspects, including a single case with familial hypercholesterolemia, other cases with different 
types of Mendelian dyslipidemias, large-scale randomized controlled trials using LDL cholesterol 
lowering therapies, and Mendelian randomization studies using common as well as rare variants asso-
ciated with LDL cholesterol levels. There is no doubt that determinations of genotypes in lipid-asso-
ciated genes have contributed not only to the genetic diagnosis for Mendelian dyslipidemias but also 
to the discoveries of novel therapeutic targets. Furthermore, recent studies have shown that such 
genetic information could provide useful clues for the risk prediction as well as risk stratification in 
general and in particular population. We provide the current understanding of genetic analyses relat-
ing to plasma lipids and coronary artery disease.
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realize the genetic architecture comprising rare vari-
ants with large effect sizes causing Mendelian dyslipid-
emia and common variants with small effect sizes caus-
ing polygenic dyslipidemias7). Due to such advances, 
we are now understanding that determination of rare 
as well as common genetic variants associated with 
lipids and CAD are quite useful not only in research 
settings but also in clinical settings.
Lessons from Patients with FH and 
Other Mendelian Dyslipidemias
(1) LDL Cholesterol as a Causal Factor for the 
Development of CAD
FH is one of the most common monogenic Men-
delian inherited disorders characterized by excess 
deposition of cholesterol in tissues leading to tendon 
xanthomas and premature CAD1, 2). It has been well 
known that FH is caused by genetic mutations of LDL 
receptor or its related proteins, including ApoB, or 
PCSK9, although a fraction of patients with clinical 
FH were unexplained by mutations in those genes1, 2). 
It is of note that even a single encounter with a patient 
with FH harboring an LDL receptor mutation could 
tell us that LDL cholesterol is a causal factor of CAD. 
Moreover, the fact that individuals with different 
mutation(s) in different gene(s) that significantly ele-
vated LDL cholesterol level exhibit premature CAD 
Introduction
Familial hypercholesterolemia (FH; OMIM #143890) 
is characterized by the triad of (1) primary hyper-
LDL-cholesterolemia, (2) tendon xanthomas, and (3) 
premature coronary artery disease (CAD)1, 2). Since 
the identification of LDL receptor in 1970s, as the 
cause of FH, three different genes have been shown to 
cause this clinical phenotype. Genetic analyses for the 
patients with FH have provided not only definitive 
diagnosis but also the chances of cascade screening for 
their offsprings3). Moreover, investigations for the 
genetic background for FH led to the development of 
novel therapeutic targets, such as proprotein conver-
tase subtilisin/kexin type 9 (PCSK9) and apolipopro-
tein B (ApoB). Moreover, observations on other Men-
delian dyslipidemias exhibiting LDL cholesterol eleva-
tion, such as sitosterolemia, and autosomal recessive 
hypercholesterolemia (ARH) convince us the causal 
role of LDL cholesterol on atherosclerosis4-6). Recent 
advances of comprehensive genetic analyses made us 
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diabetes among the patients with elevated LDL cho-
lesterol level, it may be reasonable that such costs be 
covered by insurance.
(3) Clinical Application of whole Exome Sequencing 
for Mendelian Dyslipidemias
Usefulness of whole exome sequencing (WES) 
has been shown in many Mendelian inherited diseases, 
especially, in cases with recessive form of inheri-
tance12, 13). We have demonstrated that WES is feasible 
even where DNA is available in only one individual if 
the recessive form of inheritance is firmly established 
in a family with Tangier disease caused by ATP-bind-
ing cassette transporter A1 gene mutations12). More-
over, WES could identify causative mutations in dif-
ferent genes simultaneously, where patients suffered 
from different Mendelian inherited diseases, such as 
sitosterolemia and familial Mediterranean fever5). Fur-
thermore, we also identified a rare case with heterozy-
gous FH caused by de novo LDL receptor mutation 
exhibiting recessive form of inheritance using WES14).
(4) Challenges of Identifying of Novel FH Genes
We could not determine causative mutations 
within established three FH genes (LDL receptor, ApoB, 
and PCSK9) in up to 40% of the cases with clinically 
diagnosed as FH. Such a fact has motivated research-
ers to identify novel genes causing this situation among 
the patients with genetically undetermined FH. We 
conducted WES on 213 selected family members from 
41 kindreds with suspected Mendelian inheritance of 
extreme levels of LDL cholesterol or high-density lipo-
protein (HDL) cholesterol (mainly LDL cholesterol); 
however, we failed to find any novel genes related with 
this disease (Fig.3)15). Several potential reasons could 
be considered. First, it is still hard to determine struc-
strongly convince us that LDL cholesterol is the causal 
factor of CAD, including ARH caused by LDL recep-
tor adaptor protein 1 (LDLRAP1) gene mutations and 
sitosterolemia caused by ATP-binding cassette sub-
family G member 5/8 (ABCG5/ABCG8) gene muta-
tions (Fig.1). Investigations on such extreme cases 
exhibiting Mendelian form of inheritance caused by 
(a) striking mutation(s) are one of the best ways to 
understand the roles of particular molecules and the 
causal relationship between a biomarker and an out-
come.
(2) Clinical Impact of Genetic Analyses for FH-
Associated Gene
Currently, genetic analyses for FH-associated 
genes are mostly conducted in research settings in 
most of the country, including Japan, since its cost 
cannot be covered by health insurance. Moreover, 
such analyses have been suggested as a pure diagnostic 
tool when the clinical diagnosis of FH is unclear by 
most of the guidelines8-10). Based on such backgrounds, 
few data had existed regarding the clinical impact of 
determination of genetic status of FH in the patients 
with elevated LDL cholesterol level, which could aid 
us for risk stratification in the patients suspected as 
FH. In this regard, we have assessed the prevalence of 
an FH mutation among those with severe hypercho-
lesterolemia and investigated whether CAD risk varies 
according to mutation status beyond the observed 
LDL cholesterol level and found that FH mutation 
status had substantially increased risk for CAD 
(Fig.2)11). Given that genetic analyses for FH-associ-
ated genes needed to be assessed only once in a life-
time could help identifying the individuals with the 
highest risk far before the development of other tradi-
tional acquired risk factors, such as hypertension and 
Fig.1. Mendelian dyslipidemias exhibiting hyper LDL cholesterolemia. A. Autosomal recessive hyper-
cholesterolemia caused by LDL receptor adaptor protein 1 gene mutations. B. Sitosterolemia 
caused by ATP-binding cassette subfamily G member 5 gene mutations.
26 mm
A. ARH (LDLRAP1 mutations) B. Sitosterolemia (ABCG5 mutations)
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Heritability from Common and
Rare Variants
Plasma lipids and lipoproteins are heritable risk 
factors for CAD, with heritability estimates ranging 
from 40% to 60%. Genome-wide association studies 
(GWASs) for plasma lipids and CAD have successfully 
identified 157 gene regions for plasma lipids17) and 58 
for CAD18). Despite the success of GWAS, single-
nucleotide polymorphisms (SNPs) at these loci explain 
only a modest proportion of the heritability— 20%–  
25% of the heritability for plasma lipids and ＜10% 
of the heritability of CAD. These observations have 
led to the general question of how to account for the 
unexplained heritability. To estimate such contribu-
tions, several rare variant association studies investigat-
ing on rare variants and lipids using whole genome 
sequencing and imputation-based approach have been 
performed. Those investigations have found that rare 
and low-frequency variants account for 3% –4% of 
the variance explained in lipids19-21). In contrast, we 
have demonstrated that fair portion of the missing 
heritability for lipid traits can be explained by multi-
ple common variants at each known locus22).
tural variations by WES. Accordingly, further improve-
ments in the application of approaches to discover 
structural variations using WES are needed. Second-
ary, large numbers of shared rare alleles within families 
obfuscated causal variant identification. We still need 
a large pedigree to identify a causal gene in a domi-
nant mode of inheritance. Third, we found that ~15% 
of the families suspected as Mendelian dyslipidemia 
could be polygenic carrying a significant burden of 
common lipid-related alleles, rather than one or two 
critical mutations. It is still hard to define polygenic 
Mendelian dyslipidemias, since not all variations con-
tributed to this phenotype have not been discovered.
(5) Polygenic FH
In 2013, Humphries and colleagues have dem-
onstrated that the phenotype as FH could be caused 
by the excess of LDL cholesterol-raising common vari-
ants in a substantial proportion of patients with FH 
without a known mutation, in contrast to a situation 
where a single rare variant causes significant elevation 
in LDL cholesterol level (Fig.4). Similar results were 
obtained in our analyses mentioned earlier, and we 
estimated up to 15% of the families suspected as Men-
delian dyslipidemia could be polygenic cause16).
Fig.2. Impact of clinical signs and genetic diagnosis of familial hypercholesterolemia on risk of coronary artery 
disease. Odds ratios were calculated using logistic regression after adjustment for age, sex, hypertension, 
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predisposition to CAD is not deterministic, or rather, 
genetic risk might be attenuated by a favorable life-
style and/or statin therapy. Accordingly, it may be a 
prime time for us to consider GRS as a risk assessment 
tool in clinical settings.
Mendelian Randomization
(Common and Rare)
To establish a causal relationship between a risk 
factor (usually a biomarker) and an outcome, random-
ized controlled trials (RCTs), which require a large 
amount of time and effort, are the gold standard. In 
contrast, the Mendelian randomization study is a tech-
nique that uses genotypes as instruments to assess a 
causal relationship between biomarkers and outcomes. 
In a Mendelian randomization study, a genetic variant 
associated with a particular biomarker is used as a 
proxy for the biomarker. Outcomes are compared 
between the group harboring the effect allele and a 
group with the reference allele. This approach can be 
considered a proxy for an RCT, in which the random-
ized groups have similar confounding variables. 
Accordingly, a Mendelian randomization study can be 
regarded as a natural RCT.
(1) Effect on Cardiovascular Diseases
A number of biomarkers have been shown to be 
associated with CAD from epidemiological studies. 
However, careful attention should be paid for the fact 
Genetic Risk Score for Risk 
Prediction of CAD
It is well known that CAD is highly heritable 
motivating the inclusion of family history of CAD as 
an option for risk assessment in patients with border-
line risk. Moreover, researchers have tried to identify 
genetic clues associated with CAD and found as many 
as 58 independent loci associated with CAD. How-
ever, any guideline so far does not recommend the use 
of any genetic marker for the risk assessment of CAD 
due to lack of evidence23). In this regard, Kathiresan 
and colleagues initially organized an interesting study 
investigating if aggregating information of individual 
SNPs (at that time 13 SNPs) could increase power of 
risk prediction in 201024). After that, updated genetic 
risk scores (GRSs) using increasing number of SNPs 
showed substantial clinical usefulness beyond tradi-
tional risk factors, including family history (Table 1). 
It is of note that such GRS could improve risk predic-
tion far beyond family history information25). More-
over, we can assess GRS quantitatively far before the 
development of traditional risk factors26). Interestingly, 
a recent study showed that a favorable lifestyle was 
associated with a nearly 50% lower relative risk of 
CAD than was an unfavorable lifestyle among indi-
viduals at high GRS27). Another study showed that 
individuals with the highest GRS derived the largest 
relative and absolute clinical benefit from statin ther-
apy28). Those facts collectively suggested that genetic 
Fig.3. Yield of whole exome sequencing for Mendelian dyslipidemias. The 
graph shows the percentage of final status using whole exome sequenc-
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causal roles for the development of CAD31).
Regarding other variables, a large-scale Mende-
lian randomization study has investigated the causal 
role of uric acid on CAD, heart failure, ischemic stroke, 
type 2 diabetes, and gout. They found that serum uric 
acid levels, increased by the common genetic back-
grounds, were not associated with CAD, heart failure, 
ischemic stroke, or type 2 diabetes32). Moreover, the 
patients with Lesch –Nyhan syndrome exhibiting 
increased levels of uric acid caused by rare mutations 
in hypoxanthine phosphoribosyltransferase 1 gene 
manifests with severe hyperuricemia since birth, gout, 
renal stones, and neurological impairment but not 
CAD, heart failure, ischemic stroke, or type 2 diabe-
that those biomarkers are causal or not. In the case 
with LDL cholesterol, many epidemiological studies, 
as well as Mendelian randomization studies, using rare 
as well as common genetic variants consistently showed 
that the directions and magnitude by LDL cholesterol 
level and the odds for CAD were linearly correlated. 
Moreover, those odds induced by genetically deter-
mined LDL cholesterol levels were consistently larger 
than those induced by pharmacological interventions 
(Fig.5). In contrast, common genetic variants in HDL-
raising genes did not reduce the risk of CAD29, 30). 
Interestingly, plasma triglyceride and lipoprotein (a) 
(Lp(a)) have been shown to be associated with CAD 
in Mendelian randomization studies, suggesting their 
Fig.4. Monogenic familial hypercholesterolemia (FH) and polygenic FH. X-axis represents LDL cholesterol value. 
Y-axis represents frequency. A single rare variant with large effect size or multiple single-nucleotide poly-
morphisms with modest effect sizes could elevate LDL cholesterol level substantially.
Monogenic FH









(ex. SORT1, ApoE, MYLIP)
Table 1. Comparison of power between traditional risk factors and GRS
Baseline characteristics HR (95% CI) P value
Age (per 10-year increment)
Men




Apolipoprotein B (top vs. bottom quintile)
Apolipoprotein A1 (bottom vs. top quintile)
Self-reported family history
GRS (top vs. bottom quintile)
1.86 (1.74 - 1.98)
2.50 (2.28 - 2.74)
1.07 (0.92 - 1.24)
1.81 (1.66 - 1.98)
1.69 (1.53 - 1.86)
2.43 (2.12 - 2.78)
2.39 (2.03 - 2.82)
1.87 (1.61 - 2.18)
1.41 (1.29 - 1.53)











HR: hazard ratio, GRS: genetic risk score
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associated with diabetes36). For the second question, a 
large-scale, simple observational study has suggested 
that the prevalence of diabetes in the patients with FH 
is smaller than that of non-FH, suggesting that expo-
sure of high LDL cholesterol level could be protective 
from diabetes37). Similarly, we can estimate any side 
effects by novel drugs inhibiting a particular molecule 
by investigating Mendelian diseases with large effect 
size or Mendelian randomization studies using com-
mon variants in the gene of interest.
Conclusion
It is well known that dyslipidemias and CAD are 
highly heritable diseases, motivating us to investigate 
their genetic backgrounds for a long time. Now, we 
have learned that common as well as rare genetic vari-
ants are contributing to such “heritability.” Systematic 
genetic analyses should be able to provide more clini-
cally relevant information for the assessments of the 
patients with dyslipidemias and CAD in the near 
future.
tes. Those findings from common as well as rare vari-
ants suggest that uric acid does not seem to be causally 
associated with cardiovascular diseases33).
(2) Effect on Diabetes
A meta-analysis of RCT using statin showed con-
sistent effectiveness of LDL cholesterol lowering ther-
apy on reduction of CAD. However, it also revealed 
that LDL cholesterol lowering therapy using statin 
increased the risk of diabetes34). Soon after this report, 
a Mendelian randomization study focusing on the 
effects of LDL cholesterol lowering and development 
of diabetes by variants in HMG-coenzyme A reduc-
tase (HMGCR) gene, which is the target of statin. 
They found that loss of function variants in HMGCR 
gene is associated with reduced LDL cholesterol level 
as well as increased risk of diabetes, which is consistent 
with RCT35). Next critical questions are (1) how about 
other therapies, such as ezetimibe, ApoB, and PCSK9 
and (2) how about rare variants with large effect size, 
such as the patients with FH. For the first question, a 
meta-analysis focusing on this point revealed that 
LDL cholesterol lowering alleles were associated with 
reduced risk of CAD as well as increased risk of diabe-
tes regardless of gene. Such a notion could lead us to 
speculate that LDL cholesterol is inversely but weakly 
Fig.5. Relationship between coronary artery disease (CAD) risk reduction and LDL cholesterol low-
ering. Blue line indicates the relationship between CAD risk reduction and genetic (lifelong) 
LDL cholesterol lowering. Pink line indicates the relationship between CAD risk reduction 



































Lower LDL cholesterol (mg/dl)
Pharmacological LDL cholesterol lowering





Taskinen MR, Tybjærg-Hansen A; European Atheroscle-
rosis Society Consensus Panel. Familial hypercholesterol-
aemia is underdiagnosed and undertreated in the general 
population: guidance for clinicians to prevent coronary 
heart disease: consensus statement of the European Ath-
erosclerosis Society. Eur Heart J, 2013; 34: 3478-3490a
9) Scientific Steering Committee on behalf of the Simon 
Broome Register Group. Risk of fatal coronary heart dis-
ease in familial hypercholesterolaemia. BMJ, 1991; 303: 
893-896
10) Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi 
S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, 
Kinoshita M, Maruyama C, Ohta T, Okamura T, 
Yamashita S, Yokode M, Yokote K, Harada-Shiba M, Arai 
H, Bujo H, Nohara A, Ohta T, Oikawa S, Okada T, 
Wakatsuki A. Familial hypercholesterolemia. J Atheroscler 
Thromb, 2014; 21: 6-10
11) Tada H, Kawashiri MA, Nohara A, Inazu A, Mabuchi H, 
Yamagishi M. Impact of Clinical Signs and Genetic Diag-
nosis of Familial Hypercholesterolaemia on the Prevalence 
of Coronary Artery Disease in Patients with Severe 
Hypercholesterolaemia. Eur Heart J 2017 in press
12) Tada H, Kawashiri MA, Nohara A, Saito R, Tanaka Y, 
Nomura A, Konno T, Sakata K, Fujino N, Takamura T, 
Inazu A, Mabuchi H, Yamagishi M, Hayashi K. Whole 
exome sequencing combined with integrated variant 
annotation prediction identifies asymptomatic Tangier 
disease with compound heterozygous mutations in 
ABCA1 gene. Atherosclerosis, 2015; 240: 324-329
13) Tada H, Kawashiri MA, Yamagishi M, Hayashi K. Whole 
Exome Sequencing in Monogenic Dyslipidemias. J Ath-
eroscler Thromb, 2015; 22: 881-885
14) Tada H, Hosomichi K, Okada H, Kawashiri MA, Nohara 
A, Inazu A, Tomizawa S, Tajima A, Mabuchi H, Hayashi 
K. A de novo mutation of the LDL receptor gene as the 
cause of familial hypercholesterolemia identified using 
whole exome sequencing. Clin Chim Acta, 2016; 453: 
194-196
15) Stitziel NO, Peloso GM, Abifadel M, Cefalu AB, Fouch-
ier S, Motazacker MM, Tada H, Larach DB, Awan Z, 
Haller JF, Pullinger CR, Varret M, Rabès JP, Noto D, 
Tarugi P, Kawashiri MA, Nohara A, Yamagishi M, Ris-
man M, Deo R, Ruel I, Shendure J, Nickerson DA, Wil-
son JG, Rich SS, Gupta N, Farlow DN, Neale BM, Daly 
MJ, Kane JP, Freeman MW, Genest J, Rader DJ, Mabu-
chi H, Kastelein JJ, Hovingh GK, Averna MR, Gabriel S, 
Boileau C, Kathiresan S. Exome sequencing in suspected 
monogenic dyslipidemias. Circ Cardiovasc Genet, 2015; 
8: 343-350
16) Talmud PJ, Shah S, Whittall R, Futema M, Howard P, 
Cooper JA, Harrison SC, Li K, Drenos F, Karpe F, Neil 
HA, Descamps OS, Langenberg C, Lench N, Kivimaki 
M, Whittaker J, Hingorani AD, Kumari M, Humphries 
SE. Use of low-density lipoprotein cholesterol gene score 
to distinguish patients with polygenic and monogenic 
familial hypercholesterolaemia: a case-control study. Lan-
cet, 2013; 381: 1293-1301
17) Global Lipids Genetics Consortium, Willer CJ, Schmidt 
EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, 
Ganna A, Chen J, Buchkovich ML, Mora S, Beckmann 
JS, Bragg-Gresham JL, Chang HY, Demirkan A, Den 
Acknowledgments and 
Notice of Grant Support
A scientific research grant from the Ministry of 
Education, Science, and Culture of Japan (No. 
16K19394).
Conflicts of Interest Disclosures
None.
References
1) Goldstein JL, Hobbs HH, Brown MS. Familial hypercho-
lesterolemia. In: Scriver CR, Beaudet AL, Sly WS, and 
Valle D, eds. The metabolic and molecular bases of inher-
ited disease, ed 8, vol 2. New York: McGraw-Hill; 2001: 
2863-2913
2) Soutar AK, Naoumova RP. Mechanisms of disease: genetic 
causes of familial hypercholesterolemia. Nat Clin Pract 
Cardiovasc Med, 2007; 4: 214-225
3) Tada H, Kawashiri MA, Ohtani R, Noguchi T, Nakanishi 
C, Konno T, Hayashi K, Nohara A, Inazu A, Kobayashi J, 
Mabuchi H, Yamagishi M. A novel type of familial hyper-
cholesterolemia: double heterozygous mutations in LDL 
receptor and LDL receptor adaptor protein 1 gene. Ath-
erosclerosis, 2011; 219: 663-636
4) Tada H, Kawashiri MA, Takata M, Matsunami K, Imam-
ura A, Matsuyama M, Sawada H, Nunoi H, Konno T, 
Hayashi K, Nohara A, Inazu A, Kobayashi J, Mabuchi H, 
Yamagishi M. Infantile Cases of Sitosterolaemia with 
Novel Mutations in the ABCG5 Gene: Extreme Hyper-
cholesterolaemia is Exacerbated by Breastfeeding. JIMD 
Rep, 2015; 21: 115-122
5) Tada H, Kawashiri MA, Okada H, Endo S, Toyoshima Y, 
Konno T, Nohara A, Inazu A, Takao A, Mabuchi H, Yam-
agishi M, Hayashi K. A Rare Coincidence of Sitosterol-
emia and Familial Mediterranean Fever Identified by 
Whole Exome Sequencing. J Atheroscler Thromb, 2016; 
23: 884-890
6) Tada H, Kawashiri MA, Ikewaki K, Terao Y, Noguchi T, 
Nakanishi C, Tsuchida M, Takata M, Miwa K, Konno T, 
Hayashi K, Nohara A, Inazu A, Kobayashi J, Mabuchi H, 
Yamagishi M. Altered metabolism of low-density lipopro-
tein and very-low-density lipoprotein remnant in autoso-
mal recessive hypercholesterolemia: results from stable 
isotope kinetic study in vivo. Circ Cardiovasc Genet, 
2012; 5: 35-41
7) Tada H, Kawashiri MA, Yamagishi M. Comprehensive 
genotyping in dyslipidemia: mendelian dyslipidemias 
caused by rare variants and Mendelian randomization 
studies using common variants. J Hum Genet. 2017 in 
press
8) Nordestgaard BG, Chapman MJ, Humphries SE, Gins-
berg HN, Masana L, Descamps OS, Wiklund O, Hegele 
RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts 
GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, 
Averna M, Borén J, Bruckert E, Catapano AL, Kuiven-
hoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, 
Genetic Analyses on Plasma Lipids and Coronary Artery Disease
459
Franceschini N, Gieger C, Grace C, Gustafsson S, Huang 
J, Hwang SJ, Kim YK, Kleber ME, Lau KW, Lu X, Lu Y, 
Lyytikäinen LP, Mihailov E, Morrison AC, Pervjakova N, 
Qu L, Rose LM, Salfati E, Saxena R, Scholz M, Smith 
AV, Tikkanen E, Uitterlinden A, Yang X, Zhang W, Zhao 
W, de Andrade M, de Vries PS, van Zuydam NR, Anand 
SS, Bertram L, Beutner F, Dedoussis G, Frossard P, 
Gauguier D, Goodall AH, Gottesman O, Haber M, Han 
BG, Huang J, Jalilzadeh S, Kessler T, König IR, Lannfelt 
L, Lieb W, Lind L, Lindgren CM, Lokki ML, Magnusson 
PK, Mallick NH, Mehra N, Meitinger T, Memon FU, 
Morris AP, Nieminen MS, Pedersen NL, Peters A, Rallidis 
LS, Rasheed A, Samuel M, Shah SH, Sinisalo J, Stirrups 
KE, Trompet S, Wang L, Zaman KS, Ardissino D, Boer-
winkle E, Borecki IB, Bottinger EP, Buring JE, Chambers 
JC, Collins R, Cupples LA, Danesh J, Demuth I, Elosua 
R, Epstein SE, Esko T, Feitosa MF, Franco OH, Franzosi 
MG, Granger CB, Gu D, Gudnason V, Hall AS, Ham-
sten A, Harris TB, Hazen SL, Hengstenberg C, Hofman 
A, Ingelsson E, Iribarren C, Jukema JW, Karhunen PJ, 
Kim BJ, Kooner JS, Kullo IJ, Lehtimäki T, Loos RJ, 
Melander O, Metspalu A, März W, Palmer CN, Perola M, 
Quertermous T, Rader DJ, Ridker PM, Ripatti S, Roberts 
R, Salomaa V, Sanghera DK, Schwartz SM, Seedorf U, 
Stewart AF, Stott DJ, Thiery J, Zalloua PA, O'Donnell 
CJ, Reilly MP, Assimes TL, Thompson JR, Erdmann J, 
Clarke R, Watkins H, Kathiresan S, McPherson R, 
Deloukas P, Schunkert H, Samani NJ, Farrall M; CAR-
DIoGRAMplusC4D Consortium. A comprehensive 
1,000 Genomes-based genome-wide association meta-
analysis of coronary artery disease. Nat Genet, 2015; 47: 
1121-1130
19) Helgadottir A, Gretarsdottir S, Thorleifsson G, Hjartar-
son E, Sigurdsson A, Magnusdottir A, Jonasdottir A, 
Kristjansson H, Sulem P, Oddsson A, Sveinbjornsson G, 
Steinthorsdottir V, Rafnar T, Masson G, Jonsdottir I, 
Olafsson I, Eyjolfsson GI, Sigurdardottir O, Daneshpour 
MS, Khalili D, Azizi F, Swinkels DW, Kiemeney L, 
Quyyumi AA, Levey AI, Patel RS, Hayek SS, Gudmunds-
dottir IJ, Thorgeirsson G, Thorsteinsdottir U, Gudbjarts-
son DF, Holm H, Stefansson K. Variants with large effects 
on blood lipids and the role of cholesterol and triglycer-
ides in coronary disease. Nat Genet, 2016; 48: 634-639
20) Surakka I, Horikoshi M, Mägi R, Sarin AP, Mahajan A, 
Lagou V, Marullo L, Ferreira T, Miraglio B, Timonen S, 
Kettunen J, Pirinen M, Karjalainen J, Thorleifsson G, 
Hägg S, Hottenga JJ, Isaacs A, Ladenvall C, Beekman M, 
Esko T, Ried JS, Nelson CP, Willenborg C, Gustafsson S, 
Westra HJ, Blades M, de Craen AJ, de Geus EJ, Deelen J, 
Grallert H, Hamsten A, Havulinna AS, Hengstenberg C, 
Houwing-Duistermaat JJ, Hyppönen E, Karssen LC, 
Lehtimäki T, Lyssenko V, Magnusson PK, Mihailov E, 
Müller-Nurasyid M, Mpindi JP, Pedersen NL, Penninx 
BW, Perola M, Pers TH, Peters A, Rung J, Smit JH, Stein-
thorsdottir V, Tobin MD, Tsernikova N, van Leeuwen 
EM, Viikari JS, Willems SM, Willemsen G, Schunkert H, 
Erdmann J, Samani NJ, Kaprio J, Lind L, Gieger C, Met-
spalu A, Slagboom PE, Groop L, van Duijn CM, Eriks-
son JG, Jula A, Salomaa V, Boomsma DI, Power C, Raita-
kari OT, Ingelsson E, Järvelin MR, Thorsteinsdottir U, 
Franke L, Ikonen E, Kallioniemi O, Pietiäinen V, Lind-
Hertog HM, Do R, Donnelly LA, Ehret GB, Esko T, 
Feitosa MF, Ferreira T, Fischer K, Fontanillas P, Fraser 
RM, Freitag DF, Gurdasani D, Heikkilä K, Hyppönen E, 
Isaacs A, Jackson AU, Johansson A, Johnson T, Kaakinen 
M, Kettunen J, Kleber ME, Li X, Luan J, Lyytikäinen LP, 
Magnusson PK, Mangino M, Mihailov E, Montasser ME, 
Müller-Nurasyid M, Nolte IM, O'Connell JR, Palmer 
CD, Perola M, Petersen AK, Sanna S, Saxena R, Service 
SK, Shah S, Shungin D, Sidore C, Song C, Strawbridge 
RJ, Surakka I, Tanaka T, Teslovich TM, Thorleifsson G, 
Van den Herik EG, Voight BF, Volcik KA, Waite LL, 
Wong A, Wu Y, Zhang W, Absher D, Asiki G, Barroso I, 
Been LF, Bolton JL, Bonnycastle LL, Brambilla P, Burnett 
MS, Cesana G, Dimitriou M, Doney AS, Döring A, 
Elliott P, Epstein SE, Eyjolfsson GI, Gigante B, Goodarzi 
MO, Grallert H, Gravito ML, Groves CJ, Hallmans G, 
Hartikainen AL, Hayward C, Hernandez D, Hicks AA, 
Holm H, Hung YJ, Illig T, Jones MR, Kaleebu P, 
Kastelein JJ, Khaw KT, Kim E, Klopp N, Komulainen P, 
Kumari M, Langenberg C, Lehtimäki T, Lin SY, Lind-
ström J, Loos RJ, Mach F, McArdle WL, Meisinger C, 
Mitchell BD, Müller G, Nagaraja R, Narisu N, Nieminen 
TV, Nsubuga RN, Olafsson I, Ong KK, Palotie A, Papa-
markou T, Pomilla C, Pouta A, Rader DJ, Reilly MP, Rid-
ker PM, Rivadeneira F, Rudan I, Ruokonen A, Samani N, 
Scharnagl H, Seeley J, Silander K, Stancáková A, Stirrups 
K, Swift AJ, Tiret L, Uitterlinden AG, van Pelt LJ, Vedan-
tam S, Wainwright N, Wijmenga C, Wild SH, Willemsen 
G, Wilsgaard T, Wilson JF, Young EH, Zhao JH, Adair 
LS, Arveiler D, Assimes TL, Bandinelli S, Bennett F, 
Bochud M, Boehm BO, Boomsma DI, Borecki IB, Born-
stein SR, Bovet P, Burnier M, Campbell H, Chakravarti 
A, Chambers JC, Chen YD, Collins FS, Cooper RS, 
Danesh J, Dedoussis G, de Faire U, Feranil AB, Ferrières 
J, Ferrucci L, Freimer NB, Gieger C, Groop LC, Gudna-
son V, Gyllensten U, Hamsten A, Harris TB, Hingorani 
A, Hirschhorn JN, Hofman A, Hovingh GK, Hsiung CA, 
Humphries SE, Hunt SC, Hveem K, Iribarren C, Järvelin 
MR, Jula A, Kähönen M, Kaprio J, Kesäniemi A, Kivi-
maki M, Kooner JS, Koudstaal PJ, Krauss RM, Kuh D, 
Kuusisto J, Kyvik KO, Laakso M, Lakka TA, Lind L, 
Lindgren CM, Martin NG, März W, McCarthy MI, 
McKenzie CA, Meneton P, Metspalu A, Moilanen L, 
Morris AD, Munroe PB, Njølstad I, Pedersen NL, Power 
C, Pramstaller PP, Price JF, Psaty BM, Quertermous T, 
Rauramaa R, Saleheen D, Salomaa V, Sanghera DK, Sara-
mies J, Schwarz PE, Sheu WH, Shuldiner AR, Siegbahn 
A, Spector TD, Stefansson K, Strachan DP, Tayo BO, 
Tremoli E, Tuomilehto J, Uusitupa M, van Duijn CM, 
Vollenweider P, Wallentin L, Wareham NJ, Whitfield JB, 
Wolffenbuttel BH, Ordovas JM, Boerwinkle E, Palmer 
CN, Thorsteinsdottir U, Chasman DI, Rotter JI, Franks 
PW, Ripatti S, Cupples LA, Sandhu MS, Rich SS, 
Boehnke M, Deloukas P, Kathiresan S, Mohlke KL, 
Ingelsson E, Abecasis GR. Discovery and refinement of 
loci associated with lipid levels. Nat Genet, 2013; 45: 
1274-1283
18) Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, 
Kanoni S, Saleheen D, Kyriakou T, Nelson CP, Hopewell 
JC, Webb TR, Zeng L, Dehghan A, Alver M, Armasu 
SM, Auro K, Bjonnes A, Chasman DI, Chen S, Ford I, 
Tada et al.
460
morphism genetic risk score identifies individuals at 
increased risk for future atrial fibrillation and stroke. 
Stroke, 2014; 45: 2856-2862
27) Khera AV, Emdin CA, Drake I, Natarajan P, Bick AG, 
Cook NR, Chasman DI, Baber U, Mehran R, Rader DJ, 
Fuster V, Boerwinkle E, Melander O, Orho-Melander M, 
Ridker PM, Kathiresan S. Genetic Risk, Adherence to a 
Healthy Lifestyle, and Coronary Disease. N Engl J Med. 
2016; 375: 2349-2358
28) Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield 
MJ, Devlin JJ, Nordio F, Hyde CL, Cannon CP, Sacks 
FM, Poulter NR, Sever PS, Ridker PM, Braunwald E, 
Melander O, Kathiresan S, Sabatine MS. Genetic risk, 
coronary heart disease events, and the clinical benefit of 
statin therapy: an analysis of primary and secondary pre-
vention trials. Lancet, 2015; 385: 2264-2271
29) Haase CL1, Tybjærg-Hansen A, Grande P, Frikke-
Schmidt R. Genetically elevated apolipoprotein A-I, high-
density lipoprotein cholesterol levels, and risk of ischemic 
heart disease. J Clin Endocrinol Metab, 2010; 95: E500-
510
30) Voight BF, Peloso GM, Orho-Melander M, Frikke-
Schmidt R, Barbalic M, Jensen MK, Hindy G, Hólm H, 
Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, 
Hopewell JC, Thompson JF, Li M, Thorleifsson G, New-
ton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, 
Chen L, Stewart A, Schillert A, Thorsteinsdottir U, Thor-
geirsson G, Anand S, Engert JC, Morgan T, Spertus J, 
Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, 
Patterson CC, Epstein SE, Devaney J, Burnett MS, 
Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, 
Lokki ML, Perola M, Havulinna A, de Faire U, Gigante 
B, Ingelsson E, Zeller T, Wild P, de Bakker PI, Klungel 
OH, Maitland-van der Zee AH, Peters BJ, de Boer A, 
Grobbee DE, Kamphuisen PW, Deneer VH, Elbers CC, 
Onland-Moret NC, Hofker MH, Wijmenga C, Versch-
uren WM, Boer JM, van der Schouw YT, Rasheed A, 
Frossard P, Demissie S, Willer C, Do R, Ordovas JM, 
Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Gui-
ducci C, Burtt NP, Surti A, Gonzalez E, Purcell S, Gabriel 
S, Marrugat J, Peden J, Erdmann J, Diemert P, Willen-
borg C, König IR, Fischer M, Hengstenberg C, Ziegler A, 
Buysschaert I, Lambrechts D, Van de Werf F, Fox KA, El 
Mokhtari NE, Rubin D, Schrezenmeir J, Schreiber S, 
Schäfer A, Danesh J, Blankenberg S, Roberts R, McPher-
son R, Watkins H, Hall AS, Overvad K, Rimm E, Boer-
winkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, 
Melander O, Mannucci PM, Ardissino D, Siscovick D, 
Elosua R, Stefansson K, O'Donnell CJ, Salomaa V, Rader 
DJ, Peltonen L, Schwartz SM, Altshuler D, Kathiresan S. 
Plasma HDL cholesterol and risk of myocardial infarc-
tion: a mendelian randomisation study. Lancet, 2012; 
380: 572-580
31) Jansen H, Samani NJ, Schunkert H. Mendelian random-
ization studies in coronary artery disease. Eur Heart J, 
2014; 35: 1917-1924
32) Keenan T, Zhao W, Rasheed A, Ho WK, Malik R, Felix 
JF, Young R, Shah N, Samuel M, Sheikh N, Mucksavage 
ML, Shah O, Li J, Morley M, Laser A, Mallick NH, 
Zaman KS, Ishaq M, Rasheed SZ, Memon FU, Ahmed F, 
Hanif B, Lakhani MS, Fahim M, Ishaq M, Shardha NK, 
gren CM, Stefansson K, Palotie A, McCarthy MI, Morris 
AP, Prokopenko I, Ripatti S; ENGAGE Consortium. The 
impact of low-frequency and rare variants on lipid levels. 
Nat Genet, 2015; 47: 589-597
21) Peloso GM, Auer PL, Bis JC, Voorman A, Morrison AC, 
Stitziel NO, Brody JA, Khetarpal SA, Crosby JR, Fornage 
M, Isaacs A, Jakobsdottir J, Feitosa MF, Davies G, Huff-
man JE, Manichaikul A, Davis B, Lohman K, Joon AY, 
Smith AV, Grove ML, Zanoni P, Redon V, Demissie S, 
Lawson K, Peters U, Carlson C, Jackson RD, Ryckman 
KK, Mackey RH, Robinson JG, Siscovick DS, Schreiner 
PJ, Mychaleckyj JC, Pankow JS, Hofman A, Uitterlinden 
AG, Harris TB, Taylor KD, Stafford JM, Reynolds LM, 
Marioni RE, Dehghan A, Franco OH, Patel AP, Lu Y, 
Hindy G, Gottesman O, Bottinger EP, Melander O, 
Orho-Melander M, Loos RJ, Duga S, Merlini PA, Farrall 
M, Goel A, Asselta R, Girelli D, Martinelli N, Shah SH, 
Kraus WE, Li M, Rader DJ, Reilly MP, McPherson R, 
Watkins H, Ardissino D; NHLBI GO Exome Sequencing 
Project, Zhang Q, Wang J, Tsai MY, Taylor HA, Correa A, 
Griswold ME, Lange LA, Starr JM, Rudan I, Eiriksdottir 
G, Launer LJ, Ordovas JM, Levy D, Chen YD, Reiner AP, 
Hayward C, Polasek O, Deary IJ, Borecki IB, Liu Y, Gud-
nason V, Wilson JG, van Duijn CM, Kooperberg C, Rich 
SS, Psaty BM, Rotter JI, O'Donnell CJ, Rice K, Boerwin-
kle E, Kathiresan S, Cupples LA. Association of low-fre-
quency and rare coding-sequence variants with blood lip-
ids and coronary heart disease in 56,000 whites and 
blacks. Am J Hum Genet, 2014; 94: 223-232
22) Tada H, Won HH, Melander O, Yang J, Peloso GM, 
Kathiresan S. Multiple associated variants increase the 
heritability explained for plasma lipids and coronary 
artery disease. Circ Cardiovasc Genet, 2014; 7: 583-587
23) Writing Group Members., Mozaffarian D, Benjamin EJ, 
Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de 
Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huff-
man MD, Isasi CR, Jiménez MC, Judd SE, Kissela BM, 
Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid 
DJ, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, 
Mussolino ME, Nasir K, Neumar RW, Nichol G, 
Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, 
Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, 
Virani SS, Woo D, Yeh RW, Turner MB; American Heart 
Association Statistics Committee.; Stroke Statistics Sub-
committee. Heart Disease and Stroke Statistics-2016 
Update: A Report From the American Heart Association. 
Circulation, 2016; 133: e38-360
24) Ripatti S, Tikkanen E, Orho-Melander M, Havulinna AS, 
Silander K, Sharma A, Guiducci C, Perola M, Jula A, 
Sinisalo J, Lokki ML, Nieminen MS, Melander O, Salo-
maa V, Peltonen L, Kathiresan S. A multilocus genetic 
risk score for coronary heart disease: case-control and pro-
spective cohort analyses. Lancet, 2010; 376: 1393-1400
25) Tada H, Melander O, Louie JZ, Catanese JJ, Rowland 
CM, Devlin JJ, Kathiresan S, Shiffman D. Risk predic-
tion by genetic risk scores for coronary heart disease is 
independent of self-reported family history. Eur Heart J, 
2016; 37: 561-567
26) Tada H, Shiffman D, Smith JG, Sjögren M, Lubitz SA, 
Ellinor PT, Louie JZ, Catanese JJ, Engström G, Devlin JJ, 
Kathiresan S, Melander O. Twelve-single nucleotide poly-
Genetic Analyses on Plasma Lipids and Coronary Artery Disease
461
AC, Marchioli R, Tognoni G, Sever PS, Poulter NR, 
Waters DD, Pedersen TR, Amarenco P, Nakamura H, 
McMurray JJ, Lewsey JD, Chasman DI, Ridker PM, 
Maggioni AP, Tavazzi L, Ray KK, Seshasai SR, Manson 
JE, Price JF, Whincup PH, Morris RW, Lawlor DA, 
Smith GD, Ben-Shlomo Y, Schreiner PJ, Fornage M, Sis-
covick DS, Cushman M, Kumari M, Wareham NJ, Ver-
schuren WM, Redline S, Patel SR, Whittaker JC, Ham-
sten A, Delaney JA, Dale C, Gaunt TR, Wong A, Kuh D, 
Hardy R, Kathiresan S, Castillo BA, van der Harst P, 
Brunner EJ, Tybjaerg-Hansen A, Marmot MG, Krauss 
RM, Tsai M, Coresh J, Hoogeveen RC, Psaty BM, Lange 
LA, Hakonarson H, Dudbridge F, Humphries SE, Tal-
mud PJ, Kivimäki M, Timpson NJ, Langenberg C, Assel-
bergs FW, Voevoda M, Bobak M, Pikhart H, Wilson JG, 
Reiner AP, Keating BJ, Hingorani AD, Sattar N. HMG-
coenzyme A reductase inhibition, type 2 diabetes, and 
bodyweight: evidence from genetic analysis and ran-
domised trials. Lancet, 2015; 385: 351-361
36) Lotta LA, Sharp SJ, Burgess S, Perry JR, Stewart ID, Wil-
lems SM, Luan J, Ardanaz E, Arriola L, Balkau B, Boeing 
H, Deloukas P, Forouhi NG, Franks PW, Grioni S, Kaaks 
R, Key TJ, Navarro C, Nilsson PM, Overvad K, Palli D, 
Panico S, Quirós JR, Riboli E, Rolandsson O, Sacerdote 
C, Salamanca-Fernandez E, Slimani N, Spijkerman AM, 
Tjonneland A, Tumino R, van der A DL, van der Schouw 
YT, McCarthy MI, Barroso I, O'Rahilly S, Savage DB, 
Sattar N, Langenberg C, Scott RA, Wareham NJ. Associa-
tion Between Low-Density Lipoprotein Cholesterol-Low-
ering Genetic Variants and Risk of Type 2 Diabetes: A 
Meta-analysis. JAMA, 2016; 316: 1383-1391
37) Besseling J, Kastelein JJ, Defesche JC, Hutten BA, Hov-
ingh GK. Association between familial hypercholesterol-
emia and prevalence of type 2 diabetes mellitus. JAMA, 
2015; 313: 1029-1036
Ahmed N, Mahmood K, Iqbal W, Akhtar S, Raheel R, 
O'Donnell CJ, Hengstenberg C, März W, Kathiresan S, 
Samani N, Goel A, Hopewell JC, Chambers J, Cheng 
YC, Sharma P, Yang Q, Rosand J, Boncoraglio GB, Kazmi 
SU, Hakonarson H, Köttgen A, Kalogeropoulos A, 
Frossard P, Kamal A, Dichgans M, Cappola T, Reilly MP, 
Danesh J, Rader DJ, Voight BF, Saleheen D. Causal 
Assessment of Serum Urate Levels in Cardiometabolic 
Diseases Through a Mendelian Randomization Study. J 
Am Coll Cardiol, 2016; 67: 407-416
33) Marian AJ. Genetic Causality in Complex Traits: The 
Case of Uric Acid. J Am Coll Cardiol, 2016; 67: 417-419
34) Cholesterol Treatment Trialists' (CTT) Collaborators, 
Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, 
Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The 
effects of lowering LDL cholesterol with statin therapy in 
people at low risk of vascular disease: meta-analysis of 
individual data from 27 randomised trials. Lancet, 2012; 
380: 581-590
35) Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, 
Engmann JE, Shah T, Sofat R, Stender S, Johnson PC, 
Scott RA, Leusink M, Verweij N, Sharp SJ, Guo Y, Giam-
bartolomei C, Chung C, Peasey A, Amuzu A, Li K, Pal-
men J, Howard P, Cooper JA, Drenos F, Li YR, Lowe G, 
Gallacher J, Stewart MC, Tzoulaki I, Buxbaum SG, van 
der A DL, Forouhi NG, Onland-Moret NC, van der 
Schouw YT, Schnabel RB, Hubacek JA, Kubinova R, 
Baceviciene M, Tamosiunas A, Pajak A, Topor-Madry R, 
Stepaniak U, Malyutina S, Baldassarre D, Sennblad B, 
Tremoli E, de Faire U, Veglia F, Ford I, Jukema JW, West-
endorp RG, de Borst GJ, de Jong PA, Algra A, Spiering 
W, Maitland-van der Zee AH, Klungel OH, de Boer A, 
Doevendans PA, Eaton CB, Robinson JG, Duggan D; 
DIAGRAM Consortium; MAGIC Consortium; InterAct 
Consortium, Kjekshus J, Downs JR, Gotto AM, Keech 
